|
Market Closed -
Xetra
03:06:45 2026-08-10 EDT
|
5-day change | 1st Jan Change | ||
| 14.08 EUR | -1.81% |
|
-1.81% | +164.41% |
| 07-03 | Genfit soars on news of U.S. reimbursement for a product |  |
| 07-03 | Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Research and Development of Innovative Medicines and Diagnostic Solutions | 85.36M | 26.25M | 34.48M | 70.69M | 70.84M | |||||
Total Assets | 282M | 216M | 174M | 151M | 159M | |||||
Interest Expense | -4.96M | -4.41M | -4.62M | -4.75M | -5.23M | |||||
Income Tax Expense | 2.22M | -116K | 380K | 340K | -531K | |||||
CAPEX | -537K | - | -414K | -979K | -1.39M | |||||
EBT | 69.47M | -23.84M | -28.51M | 1.85M | -86.5M | |||||
D&A | 2.59M | 1.75M | 1.59M | 1.71M | 1.83M | |||||
Operating Income | 31.82M | -27.29M | -26.58M | 3.28M | -53.63M | |||||
Net Income | 67.26M | -23.72M | -28.89M | 1.51M | -85.97M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
France | - | 20.2M | 28.56M | 67M | 65.43M | |||||
Total Assets | - | 12.92M | 13.87M | 12.58M | 12.58M | |||||
Total Assets | - | 44.16M | 46.89M | 46.08M | 46.08M |
- Stock Market
- Stocks
- GNFT Stock
- XUP Stock
- Financials GENFIT
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
